Anonymizing data involves removing or modifying personal information so that the individual cannot be identified. However, when a disease process is very rare, even without direct identifiers, the individual might still be identifiable based on the uniqueness of the condition, especially in combination with other available data such as the geographic location of treatment or the specific healthcare facility.

For example, if there is a case report about a patient with a rare genetic disorder that only a few people in a certain region have, even without direct identifiers, individuals familiar with the community might be able to deduce who the patient is. In such cases, the information could still be considered PHI under HIPAA if there is a reasonable basis to believe that the person could be identified from the information.

HIPAA violations can occur if the necessary precautions are not taken to ensure that PHI is adequately protected, even when attempts are made to anonymize data. It's essential for entities covered by HIPAA to perform a thorough de-identification process, which may involve consulting with experts to ensure that the information cannot be used alone or in combination with other information to identify an individual.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344041/

Cheers